Skip to content

US · KALA · BIOTECHNOLOGY

KALA BIO, Inc. (KALA) intrinsic value and stock valuation

$2.71as of 2026-11-21 · Mkt cap 13.56M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

KALA BIO, Inc. DCF and intrinsic value

InvestorsCraft values KALA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KALA’s statements →

KALA BIO, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Arlington, MA 02476 kalarx.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$0.00
20132025
Net income
-$-26.98M
20132025
Free cash flow
-$-31.99M
20132025
Total equity
$7M-41.2% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$3.89M$11.2M
Operating income-$-39.16M-$-40.43M-$-39.15M-$-81.36M-$-109.43M
Net income-$-26.98M-$-38.51M-$-42.2M-$-44.82M-$-142.6M
EPSd-$-3.31M-$-6.98M-$-17.37M-$-29.49M-$-109.69M
Operating cash flow-$-31.99M-$-29.38M-$-27.93M-$-78.91M-$-108.23M
Capital expenditure-$-10K-$-210K-$-610K-$-310K-$-890K
Free cash flow-$-31.99M-$-29.59M-$-28.54M-$-79.22M-$-109.12M
Total assets$9.49M$55.5M$56M$86.8M$139.4M
Total debt$0.00$32.3M$36.3M$43M$80.2M
Net debt-$-7.56M-$-18.93M-$-14.57M-$-27.55M-$-11.95M
Total equity$7M$12.3M$7.5M$19M$16.8M
Cash and short-term investments$7.56M$51.2M$50.9M$70.5M$92.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$3.89M$11.2M
Cost of revenue$0.00$260K$300K$2.56M$4.1M
Gross profit$0.00-$-260K-$-300K$1.33M$7.14M
Research and development expenses$18.8M$21.8M$18.6M$17.7M$11.5M
Selling, general and administrative expenses$23.6M$18.3M$20.3M$65M$105.1M
Other expenses-$-3.25M$0.00$0.00$0.00$0.00
Operating expenses$39.2M$40.2M$38.9M$82.7M$116.6M
Cost and expenses$39.2M$40.4M$39.2M$85.3M$120.7M
Interest income$1.14M$2.06M$2.71M$660K$100K
Interest expense$3.28M$5.78M$5.81M$7.27M$8.38M
Depreciation and amortization$320K$260K$300K$860K$2.27M
Ebitda-$-23.39M-$-32.47M-$-36.08M-$-36.7M-$-131.96M
Operating income-$-39.16M-$-40.43M-$-39.15M-$-81.36M-$-109.43M
Total other income/expenses, net$12.2M$1.92M-$-3.05M$36.5M-$-33.17M
Income before tax-$-26.98M-$-38.51M-$-42.2M-$-44.82M-$-142.6M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-26.98M-$-38.51M-$-42.2M-$-44.82M-$-142.6M
Weighted average shares outstanding$8.15M$5.52M$2.43M$1.52M$1.3M
Weighted average diluted shares outstanding$8.15M$5.52M$2.43M$1.52M$1.3M
Balance sheet
20252024202320222021
Cash and short-term investments$7.56M$51.2M$50.9M$70.5M$92.1M
Net receivables$0.00$0.00$240K$6.5M$17.5M
Inventory$0.00$0.00$0.00$0.00$8.64M
Total current assets$9.49M$52.8M$52.9M$85.9M$124.4M
Property, plant and equipment, net$0.00$2.44M$2.78M$420K$4.02M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$250K$0.00$460K$0.00
Total non-current assets$0.00$2.69M$3.08M$880K$15.1M
Total assets$9.49M$55.5M$56M$86.8M$139.4M
Accounts payable$990K$630K$920K$2.35M$4.9M
Short-term debt$0.00$10.7M$330K$5.01M$710K
Deferred revenue$0.00$640K$1.07M$4.19M$0.00
Total current liabilities$2.49M$17M$8.35M$25.7M$37.4M
Long-term debt$0.00$21.5M$36M$37.9M$79.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$26.2M$40.1M$42.2M$85.2M
Capital lease obligations$0.00$1.81M$2.13M$10K$1.26M
Total liabilities$2.49M$43.2M$48.5M$67.9M$122.6M
Common stock$30K$10K$0.00$0.00$0.00
Retained earnings-$-694.9M-$-667.92M-$-629.41M-$-587.21M-$-542.39M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$7M$12.3M$7.5M$19M$16.8M
Total investments$0.00$250K$0.00$460K$0.00
Total debt$0.00$32.3M$36.3M$43M$80.2M
Net debt-$-7.56M-$-18.93M-$-14.57M-$-27.55M-$-11.95M
Cash flow statement
20252024202320222021
Net income-$-26.98M-$-38.51M-$-42.2M-$-44.82M-$-142.6M
Depreciation and amortization$320K$260K$300K$540K$970K
Stock-based compensation$7M$8.39M$7.46M$7.01M$16.1M
Change in working capital-$-5.52M-$-1.78M$8.89M$490K-$-10.62M
Accounts receivable$0.00$0.00$80K$15.1M-$-5.76M
Inventory$0.00$0.00$7.54M$1.71M-$-6.26M
Accounts payable$360K-$-290K-$-1.9M-$-2.08M$3.23M
Net cash provided by operating activities-$-31.99M-$-29.38M-$-27.93M-$-78.91M-$-108.23M
Investments in property, plant and equipment-$-10K-$-210K-$-610K-$-310K-$-890K
Acquisitions, net$0.00$0.00$50K$62.9M-$-4.65M
Net cash used for investing activities-$-10K-$-210K-$-430K$62.7M$70.8M
Common stock issued$10.9M$26.4M$18.5M$31.8M$41.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-11.62M$29.9M$8.51M-$-7.94M$42.6M
Net change in cash-$-43.62M$290K-$-19.85M-$-24.13M$5.12M
Cash at end of period$7.56M$51.2M$50.9M$70.8M$94.9M
Operating cash flow-$-31.99M-$-29.38M-$-27.93M-$-78.91M-$-108.23M
Capital expenditure-$-10K-$-210K-$-610K-$-310K-$-890K
Free cash flow-$-31.99M-$-29.59M-$-28.54M-$-79.22M-$-109.12M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About KALA BIO, Inc.

        Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

        CEO
        Avi Minkowitz
        Employees
        6
        Beta
        -2.36

        Explore

        Frequently asked questions

        What is the intrinsic value of KALA BIO, Inc. (KALA)?

        InvestorsCraft does not currently publish an intrinsic value for KALA. How the IC value is calculated.

        Is KALA undervalued?

        InvestorsCraft does not publish an undervaluation signal for KALA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.